An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study

Table 1

Patient’s clinical-pathologic characteristics.

Characteristics
Age (years)	48 (30–63)
FIGO stage
IB2-IIA2	9 (31.0%)
IIB-IVB	20 (69.0%)
Histology
Cervical squamous cell carcinoma	25 (86.2%)
Cervical adenocarcinoma	1 (3.4%)
Cervical small cell cancer	3 (10.3%)
Sites of recurrence
Within the irradiated field	7 (24.1%)
Outside the irradiated field	17 (58.6%)
Within and outside the irradiated field	5 (17.2%)
Median number of previous chemotherapy regimens	3 (1–5)
Median interval between last treatment and disease progression (months)	2 (0–6)

FIGO: the International Federation of Gynecology and Obstetrics.